title: Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist.
abstract: BACKGROUND
  AMD3100, a selective antagonist of CXCR4, rapidly mobilizes CD34+ hematopoietic progenitor cells (HPCs) from marrow to peripheral blood with minimal side effects.
  
  
  METHODS
  To further investigate potential clinical utility of AMD3100 for CD34+ cell mobilization and collection, a Phase I study in normal volunteers was performed examining single-dose administration of AMD3100 alone and in combination with a standard 5-day granulocyte-colony-stimulating factor (G-CSF) regimen.
  
  
  RESULTS
  AMD3100 (160 microg/kg x 1 on Day 5) significantly increased both G-CSF-stimulated (10 microg/kg/day) mobilization of CD34+ cells (3.8-fold) and leukapheresis yield of CD34+ cells. Moreover, collection of CD34+ cells was comparable between individuals mobilized by a single-dose regimen of AMD3100 (240 microg/kg) and individuals mobilized with a 5-day regimen of G-CSF. AMD3100-mobilized leukapheresis products contained significantly greater numbers of T and B cells compared to G-CSF-stimulated leukapheresis products.
  
  
  CONCLUSIONS
  These findings indicate that AMD3100 can be used alone or as an adjunct to G-CSF to mobilize cells for HPC transplantation.
authors.affiliation: Department of Medicine, University of Washington, Seattle, Washington 98195, USA.
authors.forename: W Conrad
authors.initials: WC
authors.lastname: Liles
authors.forename: Elin
authors.initials: E
authors.lastname: Rodger
authors.forename: Hal E
authors.initials: HE
authors.lastname: Broxmeyer
authors.forename: Christine
authors.initials: C
authors.lastname: Dehner
authors.forename: Karin
authors.initials: K
authors.lastname: Badel
authors.forename: Gary
authors.initials: G
authors.lastname: Calandra
authors.forename: Jeff
authors.initials: J
authors.lastname: Christensen
authors.forename: Brent
authors.initials: B
authors.lastname: Wood
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Price
authors.forename: David C
authors.initials: DC
authors.lastname: Dale
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D018952:Antigens, CD34 / Q000378:metabolism; D001596:Benzylamines; D015331:Cohort Studies; D000080027:Cyclams; D004357:Drug Synergism; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000378:metabolism; D006571:Heterocyclic Compounds / Q000008:administration & dosage*; D006805:Human Experimentation; D006801:Humans
chemical_list: D019380:Anti-HIV Agents; D018952:Antigens, CD34; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor